OMVYENCE Trademark

Trademark Overview

On Tuesday, June 2, 2020, a trademark application was filed for OMVYENCE with the United States Patent and Trademark Office. The USPTO has given the OMVYENCE trademark a serial number of 88943920. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, October 8, 2024. This trademark is owned by Johnson & Johnson. The OMVYENCE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treatment of autoimmune diseases and disorders
omvyence

General Information

Serial Number88943920
Word MarkOMVYENCE
Filing DateTuesday, June 2, 2020
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, October 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 22, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for treatment of autoimmune diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 23, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameJohnson & Johnson
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew Brunswick, NJ 08933
Party NameJohnson & Johnson
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew Brunswick, NJ 08933

Trademark Events

Event DateEvent Description
Tuesday, August 18, 2020ASSIGNED TO EXAMINER
Friday, June 5, 2020NEW APPLICATION ENTERED
Tuesday, June 23, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 19, 2020NON-FINAL ACTION WRITTEN
Wednesday, August 19, 2020NON-FINAL ACTION E-MAILED
Wednesday, August 19, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 16, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 16, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 16, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 4, 2021SUSPENSION LETTER WRITTEN
Thursday, March 4, 2021LETTER OF SUSPENSION E-MAILED
Thursday, March 4, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, September 27, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, May 16, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, December 20, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, July 11, 2023SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Monday, July 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 2, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 22, 2023PUBLISHED FOR OPPOSITION
Tuesday, August 22, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 17, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, March 20, 2024SOU EXTENSION 1 GRANTED
Wednesday, March 20, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, March 20, 2024SOU EXTENSION 1 FILED
Thursday, March 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 8, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 8, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 8, 2024SOU EXTENSION 2 FILED
Tuesday, October 8, 2024SOU EXTENSION 2 GRANTED

Related Keywords

omvyence diseases disorders autoimmune treatment preparations pharmaceutical